Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida

Core Viewpoint - Journey Medical Corporation has received FDA approval for Emrosi™, a treatment for inflammatory lesions of rosacea in adults, and plans to showcase this product at the upcoming AAD Annual Meeting in March 2025 [1][2][3]. Company Overview - Journey Medical Corporation is a commercial-stage pharmaceutical company focused on marketing FDA-approved prescription products for dermatological conditions [7]. - The company currently markets seven branded and two generic products aimed at treating common skin conditions [7]. - Founded by Fortress Biotech, Inc., Journey Medical is headquartered in Scottsdale, Arizona [7]. Product Information - Emrosi™ is a modified-release formulation of Minocycline Hydrochloride, consisting of 10 mg immediate release and 30 mg extended release, and is the lowest-dose oral minocycline available [1][3]. - The product is indicated for the treatment of inflammatory lesions (papules and pustules) of rosacea in adults [4]. - Clinical outcomes for Emrosi™ are reported to be significantly superior compared to placebo and Oracea®, while maintaining a comparable safety profile [3]. Industry Context - Rosacea affects over 16 million Americans and approximately 415 million people worldwide, primarily adults aged 30 to 50 [6]. - The condition can severely impact patients' self-esteem and social interactions, with many reporting adverse effects on their professional lives [6]. Event Participation - Journey Medical will exhibit at the 2025 AAD Annual Meeting, which is a significant event in the dermatology field, featuring over 350 exhibitors and nearly 20,000 attendees [3].